Floatz logo

Therapeutic Asset Ratings

18,134 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Fludarabine
Immune System Disorder
Indapta Therapeutics, INC.P2BB (65)
Fludarabine
Immunodeficiency Disease
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsP2BB (65)
Fludarabine
Mast Cell Leukemia
Fred Hutchinson Cancer CenterP2BB (65)
Fludarabine
Metastatic Malignant Neoplasm
Beijing BiotechP2BB (65)
Fludarabine
Neuroblastoma
Robbie MajznerP2BB (65)
Fludarabine
Penile Cancer
Christian HinrichsP2BB (65)
Fludarabine
Primary Peritoneal Carcinoma
Beijing BiotechP2BB (65)
Fludarabine
Richter Transformation
Ohio State University Comprehensive Cancer CenterP2BB (65)
Fludarabine
Aplastic Anemia
Masonic Cancer Center, University of MinnesotaP2BB (65)
Fludarabine
Thymic Carcinoma
Beijing BiotechP2BB (65)
Fludarabine
Vaginal Cancer
Christian HinrichsP2BB (65)
Fludarabine
Wiskott-Aldrich Syndrome
Roswell Park Cancer InstituteP2BB (65)
Ipatasertib
Neoplasm
Hoffmann-La RocheP2BB (65)
Irinotecan
Renal Cell Carcinoma
Toray Industries, IncP2BB (65)
Lenrispodun
Parkinson Disease
Intra-Cellular Therapies, Inc.P2BB (65)
Losartan
Breast Cancer
Massachusetts General HospitalP2BB (65)
Neratinib
Breast Carcinoma
Fudan UniversityP2BB (65)
Olaparib
Malignant Pancreatic Neoplasm
MOMA TherapeuticsP2BB (65)
Oxaliplatin
Malignant Colon Neoplasm
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityP2BB (65)
Oxaliplatin
Peripheral T-Cell Lymphoma, Not Otherwise Specified
The Lymphoma Academic Research OrganisationP2BB (65)
Prednisone
B-Cell Neoplasm
Curis, Inc.P2BB (65)
Prednisone
Primary Central Nervous System Lymphoma
Juan P. Alderuccio, MDP2BB (65)
Regorafenib
Colorectal Adenocarcinoma
City of Hope Medical CenterP2BB (65)
Romidepsin
Hepatosplenic T-Cell Lymphoma
National Cancer Institute (NCI)P2BB (65)
Sapanisertib
Non-Small Cell Lung Carcinoma
Faeth TherapeuticsP2BB (65)
Showing 4001 to 4025 of 18,134 assets
PreviousPage 161 of 726Next